<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The initiation, promotion and progression of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> are complex, polygenic, multi-factored processes </plain></SENT>
<SENT sid="1" pm="."><plain>Through systematic proteomic analysis, different stages of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>) biopsies were examined, and 199 differentially expressed proteins were detected between TNM (the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, nodes, and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>) stages I-IV and <z:mpath ids='MPATH_458'>normal</z:mpath> tissue (One-Way Analysis of Variance, ANOVA; pâ‰¤ 0.05) </plain></SENT>
<SENT sid="2" pm="."><plain>Instead of looking for biomarkers to distinguish <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> from <z:mpath ids='MPATH_458'>normal</z:mpath> or identify <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e>, we focused on the variation tendency of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> and the dynamic expression patterns of proteins among the different stages </plain></SENT>
<SENT sid="3" pm="."><plain>Som (self-organizing map clustering) analysis revealed eight unique expression patterns and that the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related proteins were dynamically expressed, and their expression levels changed continuously throughout <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Molecular evidence emerged much earlier than visible, clinical or histological changes, which shows the potential prospect of building molecular staging </plain></SENT>
<SENT sid="5" pm="."><plain>Proteins identified by MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) were mainly involved in energy metabolism, acetylation and signaling pathways </plain></SENT>
<SENT sid="6" pm="."><plain>Validation experiments using immunoblotting and immunohistochemistry (IHC) agreed with the 2D-DIGE (two-dimensional difference in gel electrophoresis) data </plain></SENT>
<SENT sid="7" pm="."><plain>After survival classifier and LOOCV (leave-one-out cross-validation) analyses, the new prognostic biomarkers (78 kDa <z:chebi fb="105" ids="17234">Glucose</z:chebi>-Regulated Protein precursor (GRP78), <z:chebi fb="15" ids="28757">Fructose</z:chebi>-bisphosphate Aldolase A (ALDOA), Carbonic Anhydrase I (CA1) and Peptidyl-<z:chebi fb="0" ids="26274,32874">prolyl</z:chebi> cis-trans isomerase A or Cyclophilin A (PPIA)) provided good survival prediction for TNM stage I-IV patients </plain></SENT>
<SENT sid="8" pm="."><plain>The new biomarkers derived from the dynamic patterns of these proteins' expression provide is a good supplementary method for determining prognosis for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, especially for the TNM stage III and IV patients </plain></SENT>
</text></document>